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Portuguese beekeepers depending on blind and repeated use of amitraz in 
fighting Varroa have meant a selection pressure towards amitraz-tolerant Varroa 
populations. Some of these Varroa populations were recently pin pointed during 
a nationwide monitoring effort (by field and laboratory testing), allowing for 
investigating the practical meaning such increased levels of tolerance have to 
properly applied Apivar field treatments and how quickly those populations 
regress to normal levels of susceptibility to amitraz. 
Samples of amitraz-tolerant Varroa populations were collected in capped worker 
brood left to emerge in newly artificially built colonies. During the fol lowing 4 
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months, experimental colonies were treated twice (with Apivar and Apistan) and 
periodically assessed for (i) levels of apparent Varroa infestation in capped worker 
brood and adult bees, and (ii) daily rates of dead mature Varroa that had fallen 
to protected hive bottom boards. Finally, thymol (Apiguard) was applied to all 
experimental colonies and bees and brood samples were col lected to account for 
Varroa that could eventually have survived previous acaricide applications. 
The main results we obtained mean that Varroa populations that stood out, in field 
and laboratory tests, as being highly tolerant to amitraz, quickly revert to a status 
of high susceptibility to a properly applied Apivar treatment (overall mean efficacy 
of 78 %) if removed, for a few months, from contexts where amitraz applications 
are excessively recurrent. 
